2024 perioperative management glp-1 receptor agonists anesthesia of patients taking glucagon-like peptide 1 agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Endoscopy & GLP-1 Receptor Agonists

Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors

To provide you with control and support all day.

Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity

As global demand rises for effective metabolic therapies, GLP-1 drug development remains one of the fastest-growing segments in biopharma innovation

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline